Fibrotic NASH Index (FNI) for NAFLD/NASH Fibrosis Prediction
Non-invasive index for predicting fibrotic NASH (F2-F4 fibrosis) in patients with non-alcoholic fatty liver disease. Alternative to liver biopsy for identifying patients with advanced NAFLD needing specialist monitoring.
Score interpretation
Rule-out zone (sensitivity 0.89, NPV 0.93).
→ Low probability of fibrotic NASH; manage metabolic risk factors.
Between the rule-out and rule-in cut-offs.
→ Further assessment (elastography / referral) per local pathway.
Rule-in zone (specificity 0.90, PPV 0.57).
→ Refer to hepatology for further assessment.
Interpretation bands for the Fibrotic NASH Index. Apply clinical judgement and local guidance.
References
- Palekar NA et al. A simple score for predicting fibrotic NASH using clinical and histologic data. Dig Dis Sci. 2006;51(9):1558-1563.
- EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402.
Related
Curated clinical cross-links plus same-class fallbacks.
- Trimetazidine · Metabolic Anti-Anginal
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- L-Carnitine · Antidote / Metabolic Agent
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.
